Boceprevir

Janessa Smith, Pharm.D. BCPS, Paul A. Pham, PharmD
Boceprevir is a topic covered in the Johns Hopkins HIV Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Johns Hopkins Guides

COVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and TreatmentCOVID-19 Update with Dr. Paul Auwaerter of Johns Hopkins : Omicron Variant, Testing, and Treatment

Coronavirus COVID-19 (SARS-CoV-2)Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 PandemicSuicide Risk in the COVID-19 Pandemic

Moderna COVID-19 VaccineModerna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 VaccineJohnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

  • Boceprevir is indicated for the treatment of HCV (genotype1, used in combination with peg-INF + ribavirin) in adult patients with compensated liver disease, including cirrhosis.
    • Boceprevir may be used in either treatment-naïve patients or those who have failed previously interferon/ribavirin therapy.

There's more to see -- the rest of this entry is available only to subscribers.

© 2000–2022 Unbound Medicine, Inc. All rights reserved